HMGB1 antagonist treatment of acute lung injury
The present invention is related to the use of HMGB1 antagonists in the treatment and/or prevention and/or inhibition of acute lung injury in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists, in particular K883, in an effective amount to treat and/or prevent and/or inhibit this condition.
1. A method of treating and/or inhibiting acute lung injury in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of a peptidomimetic molecule of the formula
wherein:
R 1 is CH or N; and
R 2 is CH or N,
provided that at least one of R 1 or R 2 is N.
2. The method of claim 1 , wherein R 1 is CH and R 2 is N.
3. The method of claim 1 , wherein R 1 is N and R 2 is CH.
4. The method of claim 1 , wherein the peptidomimetic molecule is of the formula:
5. The method of claim 1 , wherein the mammal is a human.
6. The method of claim 1 , wherein the method of administration is selected from the group consisting of oral delivery, parenteral delivery, buccal delivery, sublingual delivery, nasal delivery, inhalation delivery, nebulization delivery, topical delivery, transdermal delivery and suppository delivery.
7. The method of claim 4 , wherein the peptidomimetic molecule is combined with an excipient comprising PBS:PEG 300:propylene glycol:polysorbate 80 at 50:40:5:5.
8. The method of claim 1 , wherein the therapeutically effective amount is orally administered to the mammal.
9. The method of claim 1 , wherein the therapeutically effective amount is intravenously administered to the mammal.
10. The method of claim 1 , wherein the acute lung injury is acute lung injury effects of COVID-19 or other SARS viruses.
11. The method of claim 4 , wherein the mammal is human.
12. The method of claim 4 , wherein the method of administration is selected from the group consisting of oral delivery, parenteral delivery, buccal delivery, sublingual delivery, nasal delivery, inhalation delivery, nebulization delivery, topical delivery, transdermal delivery and suppository delivery.
13. The method of claim 4 , wherein the therapeutically effective amount is orally administered to the mammal.
14. The method of claim 4 , wherein the therapeutically effective amount is intravenously administered to the mammal.
15. The method of claim 4 , wherein the acute lung injury is acute lung injury effects of COVID-19 or other SARS viruses.
16. A method of treating acute lung injury in a mammal exhibiting symptoms of acute lung injury effects of COVID-19 or other SARS viruses which comprises administering to the mammal a therapeutically effective amount of a peptidomimetic molecule of the formula
wherein:
R 1 is CH or N; and
R 2 is CH or N,
provided that at least one of R 1 or R 2 is N.
17. The method of claim 16 , wherein the peptidomimetic molecule is of the formula: